PRF Technologies’ PRF-110 Matches ZYNRELEF Efficacy with Slower Absorption and Higher Tissue Retention
PRFX•PRF Technologies reported that in a porcine model, PRF-110 and ZYNRELEF exhibited comparable analgesic efficacy via von Frey testing while PRF-110 displayed a slower absorption rate with higher local tissue Cmax. Enhanced tissue retention suggests PRF-110 may offer prolonged post-operative pain relief through single wound-bed administration.
1. Study Design and Analgesic Outcomes
The preclinical study used a validated porcine post-operative pain model and von Frey methodology to compare PRF-110 against an approved benchmark, ZYNRELEF. Both formulations achieved similar reductions in mechanical sensitivity, demonstrating equivalent analgesic efficacy over the study period.
2. Pharmacokinetic and Tissue Retention Findings
Pharmacokinetic analysis revealed that PRF-110 exhibits a slower absorption profile with increased local tissue Cmax compared with the benchmark, supporting prolonged retention at the surgical site. Sustained systemic and local drug levels were observed, indicating potential for long-acting pain control.
3. Development Plan and Next Steps
PRF Technologies plans to advance PRF-110 into additional preclinical and clinical studies to further assess safety, efficacy and surgical applicability. The company aims to position the formulation as a single-administration, opioid-sparing solution for post-operative pain management.
